Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 43382 | 28.01 |
09:34 ET | 4532 | 27.95 |
09:36 ET | 2479 | 28 |
09:38 ET | 17438 | 28.03 |
09:39 ET | 4800 | 28.05 |
09:41 ET | 2100 | 28.075 |
09:43 ET | 1872 | 28.085 |
09:45 ET | 5939 | 28.13 |
09:48 ET | 4607 | 28.114 |
09:50 ET | 2042 | 28.11 |
09:52 ET | 10572 | 28.105 |
09:54 ET | 1800 | 28.105 |
09:56 ET | 2449 | 28.065 |
09:57 ET | 1305 | 28.075 |
09:59 ET | 2917 | 28.03 |
10:01 ET | 10537 | 27.985 |
10:03 ET | 7127 | 27.97 |
10:06 ET | 1760 | 27.965 |
10:08 ET | 4609 | 27.965 |
10:10 ET | 8784 | 27.96 |
10:12 ET | 5006 | 27.978 |
10:14 ET | 3108 | 27.995 |
10:15 ET | 6775 | 28.015 |
10:17 ET | 6041 | 28.055 |
10:19 ET | 7274 | 28.065 |
10:21 ET | 3299 | 28.071 |
10:24 ET | 1616 | 28.095 |
10:26 ET | 10007 | 28.065 |
10:28 ET | 257617 | 28.065 |
10:30 ET | 919 | 28.06 |
10:32 ET | 6089 | 28.04 |
10:33 ET | 3658 | 28.005 |
10:35 ET | 10855 | 27.995 |
10:37 ET | 11822 | 27.99 |
10:39 ET | 10257 | 27.955 |
10:42 ET | 14285 | 27.975 |
10:44 ET | 12160 | 27.975 |
10:46 ET | 3954 | 27.985 |
10:48 ET | 4320 | 27.95 |
10:50 ET | 4929 | 27.92 |
10:51 ET | 6100 | 27.965 |
10:53 ET | 21547 | 28.055 |
10:55 ET | 3013 | 28.07 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.9B | 15.7x | +1.83% |
Amneal Pharmaceuticals Inc | 2.1B | -11.9x | --- |
Catalent Inc | 10.1B | -8.6x | --- |
Jazz Pharmaceuticals PLC | 6.9B | 22.7x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Roivant Sciences Ltd | 9.3B | 2.2x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.9B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 2.99% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.48 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 15.7x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | 14.2x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.